Dr. Arlene Redner, MD
Claim this profileThe Steven and Alexandra Cohen Children's Medical Center of New York
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
11 reported clinical trials
39 drugs studied
Area of expertise
1Leukemia
Philadelphia chromosome positive
BCR-ABL1 fusion positive
ABL-class fusion positive
2Lymphoblastic Leukemia-Lymphoma
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials Arlene Redner, MD is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Diagnostic Testing
for Pediatric Leukemia
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Recruiting1 award Phase 1 & 211 criteria
More about Arlene Redner, MD
Clinical Trial Related4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Arlene Redner, MD has experience with
- Cyclophosphamide
- Vincristine Sulfate
- Dexamethasone
- Pegaspargase
- Prednisolone
- Mercaptopurine
Breakdown of trials Arlene Redner, MD has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Arlene Redner, MD specialize in?
Arlene Redner, MD focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved Philadelphia chromosome positive patients, or patients who are BCR-ABL1 fusion positive.
Is Arlene Redner, MD currently recruiting for clinical trials?
Yes, Arlene Redner, MD is currently recruiting for 4 clinical trials in New Hyde Park New York. If you're interested in participating, you should apply.
Are there any treatments that Arlene Redner, MD has studied deeply?
Yes, Arlene Redner, MD has studied treatments such as Cyclophosphamide, Vincristine Sulfate, Dexamethasone.
What is the best way to schedule an appointment with Arlene Redner, MD?
Apply for one of the trials that Arlene Redner, MD is conducting.
What is the office address of Arlene Redner, MD?
The office of Arlene Redner, MD is located at: The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York 11040 United States. This is the address for their practice at the The Steven and Alexandra Cohen Children's Medical Center of New York.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.